St. Joseph's Healthcare Hamilton

Theralase Expands Bladder Cancer Clinical Trial with New Sites and Promising Phase II Data

6 months ago

• Theralase has launched new clinical study sites in the U.S. and Canada for its Phase II trial of Ruvidar™ in BCG-unresponsive NMIBC. • Phase II data shows a 61.9% complete response rate among patients, with 43.6% maintaining this response for at least 12 months. • The treatment has demonstrated a strong safety profile, with 100% of patients experiencing no serious adverse events related to the therapy. • Theralase is actively seeking partnerships for the international commercialization of Ruvidar™, with regulatory approval targeted for 2026.